Team Collaboration with Dr.PHAGE
Shanghai_United_HS & Shanghai_Metro
Since both our team and Dr.Phage team have some members who have done genetic
engineering type experiments in the lab before, we decided to enhance the projects of our two groups by
sharing our experimental experiences. We helped them by discussing and verifying their experimental steps
and inserting our plasmids carrying tke and ike into their E.Coli strains, we may use our research to
encrypt their products and prevent unauthorized uses.
Team Dr.PHAGE designed a genetically engineered probiotic guided by arabinoxylan to
secrete ClyR to prevent and treat dental caries. And our patented strain protection technology can play the
role of protecting strains. Taking this as an opportunity, we converted our opinions through online
communication, raised problems we encountered, and expressed our willingness to cooperate. In the end, we
decided to carry out various forms of cooperation, including technical and publicity.
Shanghai_Metro & Xiamen_City
After discussing with PecTeast (Xiamen_City), they discovered our team can primarily increase the value of
their project. Once They multifunctional yeast spreads out, Their customers may likely duplicate it by
themselves without their permission. Because without specific requirements of living environments, Their
yeast can increase in the most straightforward conditions.
Our project serves to protect the patent by chemically transferring a designed
plasmid into E. coli DH5α.
Therefore, we only need to extract the gene of the designed plasmid (either
ike2-tke2 or ike4-tke4, only one of them), amplify this gene by pcr, and recreate the homologous
recombination template by CRISPR-Cas technology to integrate the gene of this segment to the yeast genome.
We do not need to redesign the tke effector and ike immune factor, both universal.
After gene editing, patent protection can be achieved by simply putting the yeast into the specified
substance so as to protect their engineered yeast.
This issue greatly solves the current headache of patenting.